Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03448458 · ClinicalTrials.gov registry record · Phase 2

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

A Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase
17
Enrollment target
1
Study location

NCT03448458 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma that has completed, run by Emory University. The registered enrollment target is 17 participants, below the 78-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03448458, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in the body. Gallium Ga 68-DOTATATE PET/CT may help doctors to identify those patients with early neuroendocrine transdifferentiation and who are at greater risk for poor outcomes.

Conditions Studied

Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Stage IV Prostate Cancer AJCC v7

Interventions

  • PROCEDURE Positron Emission Tomography
  • DRUG Gallium Ga 68-DOTATATE
  • PROCEDURE CT (Computed Tomography)

Study Locations (1)

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2018-02-22
Est. Completion 2023-02-06
Phase Phase 2

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03448458

The ClinicalTrials.gov registry entry for NCT03448458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (78% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Positron Emission Tomography is the first listed.

NCT03448458 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT03448458 about?

NCT03448458 is a clinical study titled "Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer". This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in the body. Gallium Ga 68-DOTATATE PET/CT may help doctors to identify t...

What is the current status of trial NCT03448458?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2018-02-22. Estimated completion is 2023-02-06.

What conditions does trial NCT03448458 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7.

What interventions are being tested in trial NCT03448458?

The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Gallium Ga 68-DOTATATE (DRUG), CT (Computed Tomography) (PROCEDURE).

Who is sponsoring clinical trial NCT03448458?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03448458 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Castration-Resistant Prostate Carcinoma

All registered trials for this condition

Metastatic Prostate Carcinoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.